AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168876 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sophia Millington-Ward und 11 weiteren Autor:innen. Beteiligte Einrichtung: The School of Genetics and Microbiology, Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, D02VF25 Dublin, Ireland. Hauptthemen laut MEDLINE: Dependovirus, Glaucoma, Genetic Therapy, Retinal Ganglion Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland, Health Research Board, EU Marie Curie Innovation Training Network.
Abstract (Originalsprache)
Glaucoma, a leading cause of blindness, is a multifactorial condition that leads to progressive loss of retinal ganglion cells (RGCs) and vision. Therapeutic interventions based on reducing ocular hypertension are not always successful. Emerging features of glaucoma include mitochondrial dysfunction and oxidative stress. In the current study, NDI1-based gene therapy, which improves mitochondrial function and reduces reactive oxygen species, was delivered intraocularly via an adeno-associated viral vector (AAV). This AAV-NDI1 therapy protected RGCs from cell death in treated (1552.4 ± 994.0 RGCs/mm2) versus control eyes (1184.4 ± 978.4 RGCs/mm2, p < 0.05) in aged DBA/2J mice, a murine model of glaucoma. The photonegative responses (PhNRs) of RGCs were also improved in treated (6.4 ± 3.3 µV) versus control eyes (5.0 ± 3.1 µV, p < 0.05) in these mice. AAV-NDI1 also provided benefits in glaucomatous human lamina cribrosa (LC) cells by significantly increasing basal and maximal oxygen consumption rates and ATP production in these cells. Similarly, NDI1 therapy significantly protected H2O2-insulted primary porcine LC cells from oxidative stress. This study highlights the potential utility of NDI1 therapies and the benefits of improving mitochondrial function in the treatment of glaucoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The School of Genetics and Microbiology, Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, D02VF25 Dublin, Ireland.
- The Research Foundation, Royal Victoria Eye and Ear Hospital, Dublin 2, D02XK51 Dublin, Ireland.
- UCD Clinical Research Centre, Mater Misericordiae University Hospital, Dublin 7, D07K201 Dublin, Ireland.
ORCID-Profile: Sophia Millington-Ward, Arpad Palfi, Laura K Finnegan, Iris J M Post, Naomi Chadderton
Förderung
- Science Foundation Ireland
- Health Research Board
- EU Marie Curie Innovation Training Network
- Fighting Blindness Ireland - Health Research Charities Ireland
- EU Marie Curie Innovative Training Network
- Fighting Blindness Ireland—Health Research Charities Ireland
Zitieren
APA
Millington-Ward, S., Palfi, A., Shortall, C., Finnegan, L. K., Bargroff, E., Post, I. J. M., Maguire, J., Irnaten, M., O Brien, C., Kenna, P. F., Chadderton, N., & Farrar, G. J. (2024). AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168876
Vancouver
Millington-Ward S, Palfi A, Shortall C, Finnegan LK, Bargroff E, Post IJM, et al. AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168876
BibTeX
@article{MillingtonWard2024,
author = {Millington-Ward, Sophia and Palfi, Arpad and Shortall, Ciara and Finnegan, Laura K and Bargroff, Ethan and Post, Iris J M and Maguire, John and Irnaten, Mustapha and O Brien, Colm and Kenna, Paul F and Chadderton, Naomi and Farrar, G Jane},
title = {AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168876}
}
EUVIMED